Evidence map›Paper›PMID 37202533›Full record

ArticleCommunications biology2023

Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer.

Maria Kondratyev, Aleksandra Pesic, Troy Ketela, Natalie Stickle, Christine Beswick, Zvi Shalev, Stefano Marastoni, Soroush Samadian, Anna Dvorkin-Gheva, Azin Sayad and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Cancers · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Maria KondratyevPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada. mashlo88@gmail.com.ORCID 0000-0002-6871-8268
Aleksandra PesicPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.
Troy KetelaPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.
Natalie SticklePrincess Margaret Cancer Center, Bioinformatics and HPC Core, Toronto, ON, Canada.
Christine BeswickPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.
Zvi ShalevPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.
Stefano MarastoniPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.ORCID 0000-0003-1423-613X
Soroush SamadianPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.
Anna Dvorkin-GhevaPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.
Azin SayadPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.
Mikhail BashkurovSMART High-Content Screening facility at Network Biology Collaborative Centre, Toronto, ON, Canada.
Pedro BoasquevisquePrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.
Alessandro DattiSMART High-Content Screening facility at Network Biology Collaborative Centre, Toronto, ON, Canada.
Trevor J PughPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.ORCID 0000-0002-8073-5888
Carl VirtanenPrincess Margaret Cancer Center, Bioinformatics and HPC Core, Toronto, ON, Canada.
Jason MoffatDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Reidar A GrénmanTurku University Hospital, Turku, Finland.
Marianne KoritzinskyPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada.
Bradly G WoutersPrincess Margaret Cancer Centre University Health Network, Toronto, ON, Canada. Brad.Wouters@uhnresearch.ca.ORCID 0000-0002-8187-592X
University Health Network · CAPrincess Margaret Cancer Centre · CATurku University Hospital · FIUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During cancer development, tumor cells acquire changes that enable them to invade surrounding tissues and seed metastasis at distant sites. These changes contribute to the aggressiveness of metastatic cancer and interfere with success of therapy. Our comprehensive analysis of "matched" pairs of HNSCC lines derived from primary tumors and corresponding metastatic sites identified several components of Notch3 signaling that are differentially expressed and/or altered in metastatic lines and confer a dependency on this pathway. These components were also shown to be differentially expressed between early and late stages of tumors in a TMA constructed from over 200 HNSCC patients. Finally, we show that suppression of Notch3 improves survival in mice in both subcutaneous and orthotopic models of metastatic HNSCC. Novel treatments targeting components of this pathway may prove effective in targeting metastatic HNSCC cells alone or in combination with conventional therapies.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsAnimalsHumansMiceReceptor, Notch3Signal TransductionSquamous Cell Carcinoma of Head and NeckNOTCH3 protein, humanNotch3 protein, mouseReceptor, Notch3

Identifiers

PMID37202533
PMCPMC10195806
OpenAlexW4377047016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.